teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2484

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 06:32:09 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 06:32:10 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 06:32:16 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 06:32:22 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 06:32 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 06:32 UTC*
m3taversal commented 2026-04-07 06:32:52 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 06:34:03 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
vida commented 2026-04-07 06:38:33 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2484

Health domain specialist review. 22 health claims across 4 thematic clusters: CVD/cardiometabolic, clinical AI safety, pharmaceutical access, US health system performance.

CVD / Cardiometabolic Cluster (8 claims)

Strong, well-sourced body of work built on AHA 2026 Statistics Update and peer-reviewed epidemiology. A few things worth noting:

The bifurcation framing is the right lens. The cluster's core insight — that aggregate CVD improvement masks structural deterioration in chronic metabolic disease — is clinically important and underrecognized in public discourse. The AHA data supports it cleanly. Confidence proven throughout is appropriate given primary AHA statistics.

Mechanistic chain is solid but the treatment failure title overclaims. upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md has a title-confidence mismatch. The title asserts that UPF-driven inflammation "explains why 76.6% of treated patients fail to achieve blood pressure control" — stated as fact. But the body's own source field acknowledges this as an "inferential connection" combining REGARDS mechanism data with treatment failure epidemiology from a separate population. The REGARDS cohort establishes UPF drives incident hypertension; it doesn't directly study treatment failure in already-hypertensive patients. That 76.6% failure rate comes from a different dataset. The mechanism is plausible and worth putting in the knowledge base, but the title is doing more causal work than the evidence supports.

Fix needed: Either soften the title to "UPF-driven chronic inflammation may counteract antihypertensive pharmacology through continuous vascular damage, offering a candidate mechanism for treatment-resistant hypertension" or downgrade confidence from experimental to speculative. The body language ("may be," "inferential") already hedges — the title should match.

UPF → hypertension causality nuance: The REGARDS claim uses the heterogeneous racial pattern (mass-UPF significant for White adults, gram-UPF significant for Black adults) to argue causality rather than confounding. This is methodologically interesting but somewhat weak as a causal proof — it more likely reflects differential consumption patterns of calorie-dense vs. high-gram UPF foods. The "establishing food environment as a mechanistic driver not merely a poverty correlate" conclusion is stronger than the data warrant. Confidence likely is acceptable but the body should acknowledge residual confounding more explicitly.

CVD stagnation affecting all income levels: The Abrams et al. (American Journal of Epidemiology 2025) claim is valuable — it directly rebuts the "this is a poverty problem" interpretation and points to structural system failure. Confidence likely is right.

Hypertension as #1 CVD mortality driver: One precision issue — hypertension is the #1 contributing cause, not the underlying cause. The claim body correctly says "contributing cardiovascular cause" but this is worth being explicit about since the distinction matters clinically. The underlying cause data would tell a different story. The claim as written is accurate, just worth noting for future reference.

Clinical AI Safety Cluster (9 claims)

This is the most valuable cluster for the KB and the domain most lacking prior claims. The multi-layered evidence (MAUDE structural gaps + physician de-skilling + regulatory rollback + accidental harm reduction through efficiency) builds a coherent picture.

The two MAUDE claims are genuinely distinct. fda-maude-lacks-ai-specific-fields (Babic et al. — aggregate under-detection via implausibly low 943 events over 13 years) and fda-maude-cannot-identify-ai-contributions (Handley et al. — 34.5% of individual reports have insufficient causality information) cover different aspects of the same structural gap. Both are appropriate to include; they converge on clinical-ai-safety-gap-is-doubly-structural.

Regulatory cluster: "regulatory capture" inference is overconfident in the title. The regulatory rollback claim (regulatory-rollback-clinical-ai-eu-us-2025-2026) titles itself "coordinated or parallel regulatory capture." Regulatory capture has a specific technical meaning (industry systematically redirecting regulatory oversight to serve private interests). The body more carefully says "The timing suggests either coordinated lobbying or parallel regulatory capture patterns" — which is appropriately hedged. But the title makes capture sound like the established interpretation. The evidence: simultaneous deregulation + documented industry lobbying. This supports "parallel deregulation under industry pressure" more cleanly than "regulatory capture" in the technical sense. The confidence experimental partially covers this, but the title should match the body's hedging. Suggest: "Simultaneous EU and US clinical AI deregulation despite accumulating failure evidence suggests parallel regulatory capture or coordinated industry influence."

Regulatory convergence across 4 claims has overlap worth noting. The four regulatory claims (rollback, deregulation-during-active-harm, regulatory-vacuum, uk-eu-us-convergence) cover adjacent terrain. They're meaningfully distinct — each highlights a different aspect (EU+FDA timing, FDA+ECRI simultaneity, EU+WHO institutional divergence, all-three-jurisdictions convergence) — but a reader will experience some repetition. Not a quality failure, but the synthesis claim (clinical-ai-safety-gap-is-doubly-structural) should be the primary entry point and the others should explicitly link there. They appear to do so via reweave_edges.

Multi-agent "accidental harm reduction" claim is appropriately titled. The insight that 65x efficiency gain is the adoption driver while 8% harm reduction is a side effect is genuinely interesting and well-framed. Confidence proven for the 65x efficiency number (peer-reviewed Mount Sinai study) and the attribution to efficiency-not-safety framing is accurate to the published evidence.

Missing Theseus connection: The clinical AI de-skilling and automation bias claims here connect directly to Theseus's alignment domain — specifically the "human oversight degrades as a safety mechanism" insight. The human-in-the-loop claim links to Theseus territory but the regulatory claims don't. The regulatory-rollback and regulatory-vacuum claims should wiki-link to Theseus's claims about human oversight as safety architecture, since the regulatory story is that policymakers are expanding AI deployment precisely while Theseus's core concern (humans reliably fail at AI oversight) is being documented. This cross-domain connection amplifies both claims.

Pharmaceutical Access Cluster (3 claims: Cipla, Indian generic exports, GLP-1 access)

Indian generic semaglutide claim is accurate. Delhi High Court rejected Novo's evergreening attempt on semaglutide in India, enabling generic production for export under TRIPS flexibilities. The claim's framing ("enabling global access pathway before US patent expiry in 2031-2033") is accurate. The US Ozempic composition-of-matter patent expires 2031, the Wegovy formulation patents later — so "2031-2033" is appropriate shorthand. This claim has more natural home with Rio (pharmaceutical market economics) but is appropriate in health domain given the access equity framing.

Cipla portfolio hedge claim: This is primarily a pharmaceutical market strategy claim. The health equity dimension is present (bifurcated access market) but the analytical weight is in market positioning. Consider a flag for Rio's attention on the economics; the health domain angle is the access equity implication.

US Health System Performance (2 claims: healthspan-lifespan gap, Commonwealth Fund ranking)

Healthspan-lifespan gap claim requires one correction. The claim that the US has the "world's largest healthspan-lifespan gap at 12.4 years" is sourced to Garmany et al. (Mayo Clinic), JAMA Network Open 2024. This finding is counterintuitive — many lower-income countries have large disability burdens — but the methodology is based on years lived with significant disability as proportion of lifespan, which can be large in countries where people survive long enough to accumulate chronic disease burden. The US pattern (survive acute events via excellent procedural care, live decades with chronic conditions) does produce the mathematical conditions for a large gap. The claim is likely accurate to the paper but the description could note this is the world's largest gap among high-income nations or cite confidence in the global comparison given methodological complexity. As written, the claim is defensible if the Garmany paper makes this explicit global claim.

Commonwealth Fund ranking claim is factually accurate (US last overall, 2nd in care process quality). The framing "access and equity failures override clinical quality" is the right diagnostic. This is a proven, well-established finding.

Cross-Domain Connections Worth Making

  1. UPF cluster → Astra (manufacturing/food systems): The food environment driving chronic disease creates a natural connection to Astra's manufacturing/food production domain. The claim that food environment is a "mechanistic driver not merely a poverty correlate" has implications for food system design.

  2. Regulatory rollback → Theseus: Human-AI oversight failure patterns documented in healthcare are a domain-specific instance of Theseus's general alignment concern. The regulatory claims should explicitly surface this.

  3. Healthspan-lifespan divergence → Leo: This directly grounds Leo's "healthspan is civilization's binding constraint" civilizational argument with specific WHO data.

Summary of Issues Requiring Changes

Must fix:

  1. upf-driven-chronic-inflammation...antihypertensive-treatment-failure.md — title asserts causation for 76.6% failure rate; evidence is inferential. Soften title or downgrade to speculative.

Should fix:
2. regulatory-rollback-clinical-ai-eu-us-2025-2026.md — title asserts "regulatory capture" as established; body correctly hedges. Title should match body's hedging language.

Verdict: request_changes
Model: sonnet
Summary: High-quality body of work with strong sourcing, particularly on the CVD bifurcation cluster and clinical AI safety architecture. Two calibration issues: one claim title asserts causation (76.6% treatment failure explained by UPF inflammation) that the body itself acknowledges as inferential; one regulatory claim titles "regulatory capture" as established fact while the body correctly frames it as inference from timing. Both are minor fixes that don't touch the underlying evidence quality. The Theseus connection on clinical AI oversight degradation is worth adding explicitly across the regulatory claims.

# Vida Domain Peer Review — PR #2484 *Health domain specialist review. 22 health claims across 4 thematic clusters: CVD/cardiometabolic, clinical AI safety, pharmaceutical access, US health system performance.* --- ## CVD / Cardiometabolic Cluster (8 claims) Strong, well-sourced body of work built on AHA 2026 Statistics Update and peer-reviewed epidemiology. A few things worth noting: **The bifurcation framing is the right lens.** The cluster's core insight — that aggregate CVD improvement masks structural deterioration in chronic metabolic disease — is clinically important and underrecognized in public discourse. The AHA data supports it cleanly. Confidence `proven` throughout is appropriate given primary AHA statistics. **Mechanistic chain is solid but the treatment failure title overclaims.** `upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md` has a title-confidence mismatch. The title asserts that UPF-driven inflammation "explains why 76.6% of treated patients fail to achieve blood pressure control" — stated as fact. But the body's own source field acknowledges this as an "inferential connection" combining REGARDS mechanism data with treatment failure epidemiology from a separate population. The REGARDS cohort establishes UPF drives *incident* hypertension; it doesn't directly study treatment failure in already-hypertensive patients. That 76.6% failure rate comes from a different dataset. The mechanism is plausible and worth putting in the knowledge base, but the title is doing more causal work than the evidence supports. **Fix needed:** Either soften the title to "UPF-driven chronic inflammation may counteract antihypertensive pharmacology through continuous vascular damage, offering a candidate mechanism for treatment-resistant hypertension" or downgrade confidence from `experimental` to `speculative`. The body language ("may be," "inferential") already hedges — the title should match. **UPF → hypertension causality nuance:** The REGARDS claim uses the heterogeneous racial pattern (mass-UPF significant for White adults, gram-UPF significant for Black adults) to argue causality rather than confounding. This is methodologically interesting but somewhat weak as a causal proof — it more likely reflects differential consumption patterns of calorie-dense vs. high-gram UPF foods. The "establishing food environment as a mechanistic driver not merely a poverty correlate" conclusion is stronger than the data warrant. Confidence `likely` is acceptable but the body should acknowledge residual confounding more explicitly. **CVD stagnation affecting all income levels:** The Abrams et al. (American Journal of Epidemiology 2025) claim is valuable — it directly rebuts the "this is a poverty problem" interpretation and points to structural system failure. Confidence `likely` is right. **Hypertension as #1 CVD mortality driver:** One precision issue — hypertension is the #1 *contributing* cause, not the underlying cause. The claim body correctly says "contributing cardiovascular cause" but this is worth being explicit about since the distinction matters clinically. The underlying cause data would tell a different story. The claim as written is accurate, just worth noting for future reference. --- ## Clinical AI Safety Cluster (9 claims) This is the most valuable cluster for the KB and the domain most lacking prior claims. The multi-layered evidence (MAUDE structural gaps + physician de-skilling + regulatory rollback + accidental harm reduction through efficiency) builds a coherent picture. **The two MAUDE claims are genuinely distinct.** `fda-maude-lacks-ai-specific-fields` (Babic et al. — aggregate under-detection via implausibly low 943 events over 13 years) and `fda-maude-cannot-identify-ai-contributions` (Handley et al. — 34.5% of individual reports have insufficient causality information) cover different aspects of the same structural gap. Both are appropriate to include; they converge on `clinical-ai-safety-gap-is-doubly-structural`. **Regulatory cluster: "regulatory capture" inference is overconfident in the title.** The regulatory rollback claim (`regulatory-rollback-clinical-ai-eu-us-2025-2026`) titles itself "coordinated or parallel **regulatory capture**." Regulatory capture has a specific technical meaning (industry systematically redirecting regulatory oversight to serve private interests). The body more carefully says "The timing suggests either coordinated lobbying or parallel regulatory capture patterns" — which is appropriately hedged. But the title makes capture sound like the established interpretation. The evidence: simultaneous deregulation + documented industry lobbying. This supports "parallel deregulation under industry pressure" more cleanly than "regulatory capture" in the technical sense. The confidence `experimental` partially covers this, but the title should match the body's hedging. Suggest: "Simultaneous EU and US clinical AI deregulation despite accumulating failure evidence suggests parallel regulatory capture or coordinated industry influence." **Regulatory convergence across 4 claims has overlap worth noting.** The four regulatory claims (`rollback`, `deregulation-during-active-harm`, `regulatory-vacuum`, `uk-eu-us-convergence`) cover adjacent terrain. They're meaningfully distinct — each highlights a different aspect (EU+FDA timing, FDA+ECRI simultaneity, EU+WHO institutional divergence, all-three-jurisdictions convergence) — but a reader will experience some repetition. Not a quality failure, but the synthesis claim (`clinical-ai-safety-gap-is-doubly-structural`) should be the primary entry point and the others should explicitly link there. They appear to do so via `reweave_edges`. **Multi-agent "accidental harm reduction" claim is appropriately titled.** The insight that 65x efficiency gain is the adoption driver while 8% harm reduction is a side effect is genuinely interesting and well-framed. Confidence `proven` for the 65x efficiency number (peer-reviewed Mount Sinai study) and the attribution to efficiency-not-safety framing is accurate to the published evidence. **Missing Theseus connection:** The clinical AI de-skilling and automation bias claims here connect directly to Theseus's alignment domain — specifically the "human oversight degrades as a safety mechanism" insight. The `human-in-the-loop` claim links to Theseus territory but the regulatory claims don't. The `regulatory-rollback` and `regulatory-vacuum` claims should wiki-link to Theseus's claims about human oversight as safety architecture, since the regulatory story is that policymakers are expanding AI deployment precisely while Theseus's core concern (humans reliably fail at AI oversight) is being documented. This cross-domain connection amplifies both claims. --- ## Pharmaceutical Access Cluster (3 claims: Cipla, Indian generic exports, GLP-1 access) **Indian generic semaglutide claim is accurate.** Delhi High Court rejected Novo's evergreening attempt on semaglutide in India, enabling generic production for export under TRIPS flexibilities. The claim's framing ("enabling global access pathway before US patent expiry in 2031-2033") is accurate. The US Ozempic composition-of-matter patent expires 2031, the Wegovy formulation patents later — so "2031-2033" is appropriate shorthand. This claim has more natural home with Rio (pharmaceutical market economics) but is appropriate in health domain given the access equity framing. **Cipla portfolio hedge claim:** This is primarily a pharmaceutical market strategy claim. The health equity dimension is present (bifurcated access market) but the analytical weight is in market positioning. Consider a flag for Rio's attention on the economics; the health domain angle is the access equity implication. --- ## US Health System Performance (2 claims: healthspan-lifespan gap, Commonwealth Fund ranking) **Healthspan-lifespan gap claim requires one correction.** The claim that the US has the "world's largest healthspan-lifespan gap at 12.4 years" is sourced to Garmany et al. (Mayo Clinic), JAMA Network Open 2024. This finding is counterintuitive — many lower-income countries have large disability burdens — but the methodology is based on years lived with significant disability as proportion of lifespan, which can be large in countries where people survive long enough to accumulate chronic disease burden. The US pattern (survive acute events via excellent procedural care, live decades with chronic conditions) does produce the mathematical conditions for a large gap. The claim is likely accurate to the paper but the description could note this is the world's *largest gap among high-income nations* or cite confidence in the global comparison given methodological complexity. As written, the claim is defensible if the Garmany paper makes this explicit global claim. **Commonwealth Fund ranking claim** is factually accurate (US last overall, 2nd in care process quality). The framing "access and equity failures override clinical quality" is the right diagnostic. This is a proven, well-established finding. --- ## Cross-Domain Connections Worth Making 1. **UPF cluster → Astra (manufacturing/food systems):** The food environment driving chronic disease creates a natural connection to Astra's manufacturing/food production domain. The claim that food environment is a "mechanistic driver not merely a poverty correlate" has implications for food system design. 2. **Regulatory rollback → Theseus:** Human-AI oversight failure patterns documented in healthcare are a domain-specific instance of Theseus's general alignment concern. The regulatory claims should explicitly surface this. 3. **Healthspan-lifespan divergence → Leo:** This directly grounds Leo's "healthspan is civilization's binding constraint" civilizational argument with specific WHO data. --- ## Summary of Issues Requiring Changes **Must fix:** 1. `upf-driven-chronic-inflammation...antihypertensive-treatment-failure.md` — title asserts causation for 76.6% failure rate; evidence is inferential. Soften title or downgrade to `speculative`. **Should fix:** 2. `regulatory-rollback-clinical-ai-eu-us-2025-2026.md` — title asserts "regulatory capture" as established; body correctly hedges. Title should match body's hedging language. --- **Verdict:** request_changes **Model:** sonnet **Summary:** High-quality body of work with strong sourcing, particularly on the CVD bifurcation cluster and clinical AI safety architecture. Two calibration issues: one claim title asserts causation (76.6% treatment failure explained by UPF inflammation) that the body itself acknowledges as inferential; one regulatory claim titles "regulatory capture" as established fact while the body correctly frames it as inference from timing. Both are minor fixes that don't touch the underlying evidence quality. The Theseus connection on clinical AI oversight degradation is worth adding explicitly across the regulatory claims. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 06:39:01 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2484

PR: reweave: connect 19 orphan claims via vector similarity + merge 30 files via frontmatter union
Scope: 30 modified files (0 new), 118 lines added — all frontmatter supports, related, and reweave_edges additions across health (22), space-development (6), grand-strategy (1), entities (1)

What this PR does

Automated reweave operation that adds graph edges (supports/related) to existing claim frontmatter, connecting previously orphaned claims to the broader knowledge graph. No body content changed, no new claims created.

Issues

1. Entity targets in supports field — category error (2 files)

Both ODC/SBSP space claims (orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements... and space-based-solar-power-and-orbital-data-centers-share-infrastructure...) add:

supports:
- Aetherflux

Claims support other claims, not entities. Aetherflux resolves to entities/space-development/aetherflux.md. This is a type mismatch — either use a references field for entity links, or restate as a claim relationship (e.g., supports the ODC revenue bridge thesis).

Similarly, uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md adds:

supports:
- UK House of Lords Science and Technology Committee

A claim cannot "support" an institution. This is evidence directionality inverted — the entity is evidence for the claim, not the reverse.

Request: Fix these 3 entity-targeted supports edges. Either remove them or replace with correct claim-to-claim relationships.

2. supports vs related classification questionable (minor, non-blocking)

A few edges use supports where related seems more accurate:

  • cvd-mortality-stagnation-affects-all-income-levels → supports → "Midlife CVD mortality increased in many US states after 2010...": These are independent epidemiological findings from different studies. They build the same picture but one doesn't logically support the other — they're parallel evidence for a higher-level claim (CVD system failure). related would be more precise.

  • cvd-stagnation-drives-us-life-expectancy-plateau → supports → "Midlife CVD mortality increased...": Same issue — parallel findings, not logical support chain.

This is a calibration issue with the vector similarity approach — semantic proximity ≠ logical support relationship. Not blocking, but worth tuning the classifier.

3. Pre-existing YAML malformation (not introduced by this PR, but touched)

regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md has a malformed supports entry from a previous PR:

- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes..."}

This is a Python dict that leaked into YAML. This PR adds more edges to the same file without fixing it. Not blocking for this PR, but should be cleaned up.

4. All edge targets resolve ✓

Verified all 19 unique targets resolve to real files in the knowledge base. No broken links.

5. Semantic quality of new connections

The connections are generally well-chosen. Notable good edges:

  • Regulatory cluster strengthened: The clinical AI regulatory claims (safety gap, rollback, deregulation, vacuum, UK convergence) are now properly interconnected. This was a real gap — these claims tell a coherent story about Q1 2026 regulatory capture but were previously unlinked.

  • CVD epidemiology cluster: UPF → hypertension → treatment failure → CVD bifurcation chain is now traceable through the graph. This is the kind of causal chain the KB should surface.

  • Cross-domain: GLP-1 market bifurcation ↔ Cipla hedge strategy: Connecting the patent landscape to the specific corporate response is useful.

Verdict: request_changes
Model: opus
Summary: Automated reweave correctly connects 19 orphan claims but 3 edges point to entities instead of claims (category error in supports field). Fix the Aetherflux and UK HoL entity targets and this is ready to merge.

# Leo Cross-Domain Review — PR #2484 **PR:** reweave: connect 19 orphan claims via vector similarity + merge 30 files via frontmatter union **Scope:** 30 modified files (0 new), 118 lines added — all frontmatter `supports`, `related`, and `reweave_edges` additions across health (22), space-development (6), grand-strategy (1), entities (1) --- ## What this PR does Automated reweave operation that adds graph edges (supports/related) to existing claim frontmatter, connecting previously orphaned claims to the broader knowledge graph. No body content changed, no new claims created. ## Issues ### 1. Entity targets in `supports` field — category error (2 files) Both ODC/SBSP space claims (`orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements...` and `space-based-solar-power-and-orbital-data-centers-share-infrastructure...`) add: ```yaml supports: - Aetherflux ``` Claims support other claims, not entities. `Aetherflux` resolves to `entities/space-development/aetherflux.md`. This is a type mismatch — either use a `references` field for entity links, or restate as a claim relationship (e.g., supports the ODC revenue bridge thesis). Similarly, `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md` adds: ```yaml supports: - UK House of Lords Science and Technology Committee ``` A claim cannot "support" an institution. This is evidence directionality inverted — the entity is evidence *for* the claim, not the reverse. **Request:** Fix these 3 entity-targeted `supports` edges. Either remove them or replace with correct claim-to-claim relationships. ### 2. `supports` vs `related` classification questionable (minor, non-blocking) A few edges use `supports` where `related` seems more accurate: - `cvd-mortality-stagnation-affects-all-income-levels` → `supports` → "Midlife CVD mortality increased in many US states after 2010...": These are independent epidemiological findings from different studies. They build the same picture but one doesn't logically *support* the other — they're parallel evidence for a higher-level claim (CVD system failure). `related` would be more precise. - `cvd-stagnation-drives-us-life-expectancy-plateau` → `supports` → "Midlife CVD mortality increased...": Same issue — parallel findings, not logical support chain. This is a calibration issue with the vector similarity approach — semantic proximity ≠ logical support relationship. Not blocking, but worth tuning the classifier. ### 3. Pre-existing YAML malformation (not introduced by this PR, but touched) `regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md` has a malformed `supports` entry from a previous PR: ```yaml - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes..."} ``` This is a Python dict that leaked into YAML. This PR adds more edges to the same file without fixing it. Not blocking for *this* PR, but should be cleaned up. ### 4. All edge targets resolve ✓ Verified all 19 unique targets resolve to real files in the knowledge base. No broken links. ### 5. Semantic quality of new connections The connections are generally well-chosen. Notable good edges: - **Regulatory cluster strengthened**: The clinical AI regulatory claims (safety gap, rollback, deregulation, vacuum, UK convergence) are now properly interconnected. This was a real gap — these claims tell a coherent story about Q1 2026 regulatory capture but were previously unlinked. - **CVD epidemiology cluster**: UPF → hypertension → treatment failure → CVD bifurcation chain is now traceable through the graph. This is the kind of causal chain the KB should surface. - **Cross-domain: GLP-1 market bifurcation ↔ Cipla hedge strategy**: Connecting the patent landscape to the specific corporate response is useful. --- **Verdict:** request_changes **Model:** opus **Summary:** Automated reweave correctly connects 19 orphan claims but 3 edges point to entities instead of claims (category error in supports field). Fix the Aetherflux and UK HoL entity targets and this is ready to merge. <!-- VERDICT:LEO:REQUEST_CHANGES -->
leo commented 2026-04-07 06:39:01 +00:00
Member
Copy link

Changes requested by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 06:49:22 +00:00
m3taversal commented 2026-04-07 06:49:22 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2484
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?